The 2008 and 2014 VA (RAC) reports and the 2010 IOM report found that the chronic multisymptom illness in<unk> <unk>  veterans—Gulf<unk>  illness—is more prevalent in<unk> <unk>  veterans than their non-deployed counterparts or veterans of previous conflicts. While a 2009 study found the pattern of comorbidities similar for actively deployed and nondeployed Australian military personnel, the large body of U.S. research reviewed in the VA and IOM reports showed the opposite in U.S. troops. The VA's 2014 RAC report found<unk> <unk>  illness in "an excess of 26–32 percent of<unk> <unk>  veterans compared to nondeployed era veterans" in pre-2008 studies, and "an overall multisymptom illness prevalence of 37 percent in<unk> <unk>  veterans and an excess prevalence of 25 percent" in a later, larger VA study. According to a May 2018 report by the U.S. Department of Defense, "GWI is estimated to have affected 175,000 to 250,000 of the nearly 700,000 troops deployed to the 1990–1991 GW theater of operations. Twenty-seven of the 28 Coalition members participating in the GW conflict have reported GWI in their troops. Epidemiologic studies indicate that rates of GWI vary in different subgroups of GW Veterans. GWI affects Veterans who served in the U.S. Army and Marines Corps at higher rates than those who served in the Navy and Air Force, and U.S. enlisted personnel are affected more than officers. Studies also indicate that GWI rates differ according to where Veterans were located during deployment, with the highest rates among troops who served in forward areas."
Gulf War syndrome
SAHA syndrome
Toxic shock syndrome
Primrose syndrome
Proteus syndrome
Systemic inflammatory response syndrome
SUNCT syndrome
Severe fever with thrombocytopenia syndrome